DLG1 and neoplasm: Whether these effects on epithelial architecture modulate EGFR-RAS-ERK activation (perhaps through altering SCRIB/DLG1 function) or affect other signaling pathways to contribute to the tumor suppressor function of Tsp29Fb/TSPAN6 needs to be examined.